Showing results (101-110 of 126) with videos related to
Sort By:
Pageof 13
Oncotarget|December 13, 2017
Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trialsMichitaka Honda, Koji Oba, Takashi Akiyoshi, et al.Frontiers in Psychology|May 19, 2025
Is scenery mandatory for restoration? Attention restoration without visual nature elementsHiroto Sakimura, Tomoko Sugawara, Kohta Watatsu, et al.Cancer Science|May 23, 2025
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural MesotheliomaTakashi Kijima, Terufumi Kato, Yasushi Goto, et al.Diabetes Care|June 28, 2006
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications TrialNigishi Hotta, Yasuo Akanuma, Ryuzo Kawamori, et al.The Lancet. Oncology|September 7, 2012
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialTakayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|March 19, 2019
Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese womenMasaru Sakamoto, Etsuko Miyagi, Yukari Sumi, et al.The Lancet. Infectious Diseases|August 3, 2026
Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trialKoji Hisamoto, Masaki Yamanaka, Masayasu Nomura, et al.Plos One|May 10, 2014
A prospective stratified case-cohort study on statins and multiple adverse events in JapanNobuhiro Ooba, Tsugumichi Sato, Akira Wakana, et al.British Journal of Cancer|March 6, 2019
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 studyNaohiro Tomita, Katsuyuki Kunieda, Atsuyuki Maeda, et al.Cancer Chemotherapy and Pharmacology|April 19, 2014
Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trialTakashi Tsuchiya, Sotaro Sadahiro, Kazuaki Sasaki, et al.Pageof 13